BRAF V600E-mutant Colorectal Cancer Study of Encorafenib Taken With Cetuximab Plus or Minus Chemotherapy (BREAKWATER)

Condition:   Neoplasms Interventions:   Drug: Encorafenib;   Drug: Cetuximab;   Drug: Oxaliplatin;   Drug: Irinotecan;   Drug: Leucovorin;   Drug: 5-FU;   Drug: Capecitabine;   Drug: Bevacizumab Sponsors:   Pfizer;   Ono Pharmaceutical Co. Ltd;   Merck KGaA, Darmstadt, Germany Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials